0001209191-15-022712.txt : 20150304
0001209191-15-022712.hdr.sgml : 20150304
20150304213951
ACCESSION NUMBER: 0001209191-15-022712
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150302
FILED AS OF DATE: 20150304
DATE AS OF CHANGE: 20150304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAST ERLE T
CENTRAL INDEX KEY: 0001051411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 15675610
MAIL ADDRESS:
STREET 1: C/O SPIROS DEVELOPMENT CORP II INC
STREET 2: 7475 LUSK BLVD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-03-02
0
0001466301
Clovis Oncology, Inc.
CLVS
0001051411
MAST ERLE T
C/O CLOVIS ONCOLOGY, INC.
2525 28TH STREET, SUITE 100
BOULDER
CO
80301
0
1
0
0
Executive VP and CFO
Stock Option (right to buy)
79.05
2015-03-02
4
A
0
35000
0.00
A
2025-03-02
Common Stock
35000
35000
D
The option shall vest as to 12.5% of the shares on March 2, 2016, and as to 37.5% of the shares in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 25% of the shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib and the remaining 25% shall vest upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib.
/s/ Erle T. Mast
2015-03-04